Next-Generation GLP-1s: Oral Semaglutide, Retatrutide, and What's Coming
Last updated: 8 August 2026
TL;DR: The next wave of weight loss medicines includes oral semaglutide (a pill form of the Wegovy/Ozempic active ingredient), the established dual-agonist tirzepatide (Mounjaro), and investigational triple-agonist retatrutide. Formats are widening from weekly injections to daily pills, and multi-receptor drugs are pushing efficacy higher in trials, though availability differs sharply by product.
The GLP-1 field is moving fast, and the questions patients ask, "is there a pill?", "what is retatrutide?", "what comes after Mounjaro?", are getting ahead of clear answers. This guide maps the current generation and what is in development, with an honest note on what is actually available in the UK versus still in trials.
What Are the Next-Generation GLP-1 Medications?
The category is expanding along two axes: format (injection to oral) and mechanism (single-hormone to multi-hormone). The first generation of weight loss GLP-1 medicines were weekly injections acting on one receptor; the newer wave adds pills and drugs that act on two or three hormone receptors at once.
| Medicine | Type | Format | UK status (Aug 2026) |
|---|---|---|---|
| Semaglutide (Wegovy / Ozempic) | GLP-1 agonist | Weekly injection | Licensed |
| Oral semaglutide (Rybelsus; higher-dose obesity forms) | GLP-1 agonist | Daily pill | Licensed for type 2 diabetes; obesity forms rolling out |
| Tirzepatide (Mounjaro) | GIP + GLP-1 dual agonist | Weekly injection | Licensed |
| Retatrutide | GIP + GLP-1 + glucagon triple agonist | Weekly injection | Investigational (not licensed) |
The practical takeaway: more choice is coming, but "in trials" and "available now" are very different things, and the sections below keep that distinction clear.
How Does Oral Semaglutide Differ From the Injection?
Oral semaglutide delivers the same active ingredient as the Wegovy and Ozempic injections in a daily tablet rather than a weekly injection. The trade-off is convenience and needle-avoidance against a strict dosing routine: it must be taken on an empty stomach with a small sip of water and a wait before eating or drinking.
The oral form is well studied. According to the PIONEER programme (published across journals including Diabetologia, 2024), oral semaglutide demonstrated efficacy for glycaemic control and weight reduction in type 2 diabetes, and higher-dose oral formulations have been developed for obesity. For many patients the choice between pill and injection comes down to routine and preference rather than a large efficacy gap.
What Is Retatrutide and Why Is It Significant?
Retatrutide is an investigational triple-agonist that acts on GIP, GLP-1 and glucagon receptors, and it has produced the largest weight reductions yet seen in trials. According to a Phase 2 obesity trial (Jastreboff et al., New England Journal of Medicine, 2023), retatrutide achieved a mean weight reduction of roughly 24% at 48 weeks at the highest dose.
Phase 3 evidence is now emerging: according to TRANSCEND-T2D-1 (The Lancet, 2026), retatrutide was assessed in a large randomised trial in type 2 diabetes. It is not yet licensed and is not available to prescribe, so it belongs in the "what's coming" column rather than the "options now" column. Its significance is directional: it signals where efficacy may go, not what patients can access today.
Which New GLP-1 Formats Are Available in the UK Now?
Availability is the question that matters most, and it varies by product. Weekly injections of semaglutide (Wegovy) and tirzepatide (Mounjaro) are licensed and prescribed in the UK. Oral semaglutide is licensed for type 2 diabetes, with obesity-indicated oral forms rolling out. Retatrutide remains investigational.
- Available now: Wegovy and Mounjaro weekly injections; oral semaglutide for type 2 diabetes.
- Emerging: higher-dose oral semaglutide for weight management.
- In development: retatrutide and other multi-agonists, not yet licensed.
Because status changes, eligibility and current licensing should always be confirmed with a prescriber rather than assumed from headlines. For a direct comparison of the two established injections, see the related Mounjaro vs Wegovy guide.
What Should Patients Expect From the 2026 Pipeline?
Expect more formats and higher trial efficacy, alongside the same class of side effects and the same need for clinical supervision. Multi-receptor drugs tend to produce greater weight loss in trials but share the gastrointestinal side-effect profile of the class, managed the same way through slow dose escalation.
The headline for patients is choice with caution: a pill may suit those who dislike injections; newer agents may offer more effect but are not yet available. According to SURMOUNT-5 (New England Journal of Medicine, 2025), tirzepatide and semaglutide have now been compared head-to-head for obesity, a sign the field is maturing from single options to genuine comparison. The right medicine remains the one matched to the individual by a prescriber, not the newest name in the news.
Related Guides
- Mounjaro vs Wegovy: How the Two Weight Loss Injections Compare
- Wegovy Pill vs Injection: What the Oral Option Changes
- How to Manage Common GLP-1 Side Effects: A Practical Patient Guide
- Who Should Not Take GLP-1 Weight Loss Medication? Contraindications Explained
- Am I Eligible for Weight Loss Medication?
Key Takeaways
- Next-generation GLP-1 medicines are widening in format (injection to pill) and mechanism (single to multi-receptor).
- Oral semaglutide delivers the Wegovy/Ozempic active ingredient as a daily pill with a strict dosing routine.
- Retatrutide, a triple-agonist, reached roughly 24% mean weight reduction at 48 weeks in a Phase 2 obesity trial, but is not licensed.
- Wegovy and Mounjaro injections are licensed in the UK; retatrutide remains investigational.
- Newer multi-agonists show greater trial efficacy but share the class side-effect profile.
- Current licensing and eligibility should be confirmed with a prescriber, not assumed from headlines.
Frequently Asked Questions
Is there a weight loss pill instead of an injection?
Yes. Oral semaglutide is a daily tablet form of the same active ingredient as the Wegovy and Ozempic injections. It is licensed for type 2 diabetes, with obesity-indicated oral forms rolling out. It must be taken on an empty stomach with a strict routine.
What is retatrutide?
Retatrutide is an investigational triple-agonist acting on GIP, GLP-1 and glucagon receptors. In a Phase 2 obesity trial (NEJM, 2023) it achieved around 24% mean weight reduction at 48 weeks at the highest dose. It is not yet licensed and cannot currently be prescribed.
Is the Wegovy pill as effective as the injection?
Oral semaglutide delivers the same active ingredient, and for many patients the choice is about routine and preference rather than a large efficacy gap. Effectiveness depends on dose and adherence to the strict daily routine the pill requires. A prescriber can advise on the right format.
What comes after Mounjaro?
The pipeline includes higher-dose oral semaglutide for weight management and investigational multi-agonists such as retatrutide, which show greater weight loss in trials. These are emerging or not yet licensed, so current options remain the established injections and oral semaglutide.
Published by Bolt Pharmacy, a GPhC-registered UK pharmacy. Sources: Jastreboff et al., New England Journal of Medicine (2023); TRANSCEND-T2D-1, The Lancet (2026); PIONEER programme, Diabetologia (2024); SURMOUNT-5, New England Journal of Medicine (2025). Educational only; not a substitute for professional medical advice. Licensing and availability reflect published information as of August 2026 and may change.
